Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

Share Price is delayed by 15 minutes
Get Live Data
9.00    0.00 (0.00%)
Bid:
7.00
Ask:
11.00
Spread: 4.00 (57.143%)
Market Cap: £2.98m
HYG Live PriceLast checked at - London Stock Exchange

Intraday Seneca Growth Share Chart

Net Asset Value(s)

4 Apr 2023 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2023

Net asset values (β€œNAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (β€œSeneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2023.

B Shares

As at 31 March 2023, the unaudited NAV per B share was 73.8p and it is intended that this is the NAV per B share which will be used for the planned allotment of B shares on 5 April 2023.

This is a decrease of 8.8p from the latest published unaudited NAV of 82.6p as at 30 September 2022, predominantly as a result of a reduction in the share prices of some of the B share pool’s AIM quoted investments.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2023 was 85.8p.

The unaudited NAV per B share as at 31 DecemberΒ 2022 was 80.7p, full details of which will be included in our Final Results announcement later this month.

The B share Offer by the Company remains open for the 2022/23 tax year until midday today, 4 April 2023.

The B share Offer remains open for the 2023/24 tax year until 18 August 2023, unless the Offer has been fully subscribed by an earlier date or is closed earlier at the discretion of the Directors.

Ordinary Shares

As at 31 March 2023, the unaudited NAV per Ordinary share was 28.4p.

This is a decrease of 11.6p from the latest published unaudited NAV as at 5 December 2022 of 40.0p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc offset by an increase in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2023, shares in Scancell Holdings Plc were valued at 15.5p per share (5 December 2022: 23p) and shares in Arecor Therapeutics Plc were valued at 250p per share (5 December 2022: 240p).

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2023 was 99.7p.

The unaudited NAV per Ordinary share as at 31 DecemberΒ 2022 was 37.1p, full details of which will be included in our Final Results announcement later this month.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc atΒ john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc atΒ Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or atΒ Matt.Currie@senecapartners.co.uk

Date   Source Headline
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend
6th Mar 20198:39 amRNSNet Asset Value(s)
28th Dec 20187:00 amRNSDividend Declaration
19th Dec 20182:21 pmRNSIssue of Equity
18th Dec 20189:56 amRNSUpdate on Hallmarq
17th Dec 20184:43 pmRNSReduction of Capital
29th Nov 20181:53 pmRNSHolding(s) in Company
23rd Nov 20187:00 amRNSUpdate for the quarter ended 30 September 2018
27th Sep 201810:59 amRNSIssue of Equity
23rd Apr 201812:43 pmRNSHolding(s) in Company
22nd May 201712:59 pmRNSHolding(s) in Company
24th Feb 201610:42 amRNSScancell to present at Biotech Capital
16th Feb 20159:47 amRNSHoldings in Company
24th Oct 20133:53 pmRNSInterim Management Statement
22nd Mar 20127:00 amRNSFinal Results
29th Oct 201011:18 amRNSInterim Management Statement
7th Sep 201011:34 amRNSDirector's Dealings
5th Aug 20107:00 amRNSHalf Yearly Report
7th May 20107:00 amRNSResults of AGM and IMS to 31 March 2010
31st Mar 20104:48 pmRNSAnnual Financial Report
22nd Jan 201012:26 pmRNSDeclaration of Interim Dividend
24th Sep 20099:43 amRNSDirector's Dealing
22nd Sep 200910:10 amRNSPortfolio Update
19th May 20099:42 amRNSIssue of Equity
15th May 20093:27 pmRNSIssue of Equity
12th May 20097:00 amRNSInterim Management Statement
6th May 20097:00 amRNSResults of AGM and Issue of Equity
30th Apr 20097:00 amRNSTotal Voting Rights
16th Apr 20097:00 amRNSAvailability of Annual Accounts and Offer Letter
9th Apr 20091:04 pmRNSIssue of Equity-Replacement
9th Apr 200912:41 pmRNSIssue of Equity
9th Apr 200912:39 pmRNSOffer to Shareholders
6th Apr 20094:32 pmRNSDirector's Dealings
2nd Apr 20097:00 amRNSAnnual Report & Accounts and Notice of AGM
19th Nov 20089:54 amRNSDirector's Dealings
14th Nov 20081:08 pmRNSInterim Management Statement
28th Aug 20087:00 amRNSInterim Results
1st Aug 20084:00 pmRNSIssue of Equity
22nd Jul 20083:11 pmRNSResult of AGM
30th May 20083:25 pmRNSIssue of Equity
15th May 20087:00 amRNSInterim Management Statement
1st May 200810:55 amRNSIssue of Equity
8th Apr 20085:18 pmRNSAnnual Information Update
3rd Apr 20083:42 pmRNSIssue of Equity
19th Mar 20085:02 pmRNSOffer to shareholders

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.